← All Synlogic, INC filings

Synlogic, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
SYBX
Synlogic, INC
10-K/A: Synlogic Files 10-K/A for Governance and Compensation
Synlogic, Inc. filed an amendment to its 2025 Annual Report to provide previously omitted disclosures regarding corporate governance, executive compensation, and related party transactions.
OTC.Pink
SYBX
Synlogic, INC
10-K: Synlogic Halts Lead Trial, Delists from Nasdaq, Becomes Shell
Synlogic, a biopharmaceutical company, has discontinued its lead clinical program and delisted from Nasdaq, now focusing on strategic alternatives as a public shell company.
OTC.Pink
SYBX
Synlogic, INC
10-K/A: Synlogic Files Amended 10-K to Include Omitted Executive and Governance Information
Synlogic files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and accounting fees.
OTC.Pink
SYBX
Synlogic, INC
10-K: Synlogic Discontinues Phase 3 PKU Trial, Explores Strategic Alternatives
Synlogic halts its pivotal PKU study due to unfavorable internal review, shifting focus to strategic options like a merger or sale to boost stockholder value.
OTC.Pink
SYBX
Synlogic, INC
10-K/A: Synlogic Files Amended 10-K to Include Omitted Executive and Governance Details
Synlogic, Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.
OTC.Pink
SYBX
Synlogic, INC
10-K: Synlogic Halts Phase 3 PKU Trial, Explores Strategic Alternatives Including Potential Sale
Synlogic discontinues its pivotal Phase 3 study for labafenogene marselecobac (SYNB1934) in PKU and initiates a strategic review process, including a possible merger or sale of the company.